Antiretroviral-induced toxiderma in HIV-infected patients;Toxidermies dues aux antirétroviraux chez les patients infectés par le VIH

Presse Medicale

Volumn 32, Issue 28, 2003, Pages 1325-1333

  Caumes, Éric ^a   Bossi, Philippe ^a   Katlama, Christine ^a   Bricaire, François ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN DERIVATIVE; CETIRIZINE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PREDNISOLONE; PROTEINASE INHIBITOR; PYRIMETHAMINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SULFADIAZINE; SULFANILAMIDE; THALIDOMIDE; UNINDEXED DRUG; VANCOMYCIN; ZALCITABINE; ZIDOVUDINE;

BACTERIAL INFECTION; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS INFECTION;

ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; HISTAMINE H1 ANTAGONISTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STEROIDS; STEVENS-JOHNSON SYNDROME;

EID: 0041334113     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Wolkenstein P, Roujeau JC. Toxidermies. Editions techniques - Encycl. Med. Chir. (Paris-France), Dermatologie 12-930-A-10; 1995.
2. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670-4.
3. Salag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-74.
4. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
5. Caumes E. Rash morbilliforme, rubéoliforme et autre scarlatiniforme; une terminologie obsolète. Ann Dermatol Venereol 2002; 129: 685-7.
6. Bonfanti P, Capetti A, Riva P, Testa L, Quirino T. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS 1997; 11: 1301-2.
7. Fortuny C, Vicente MA, Medina MM, Gonzalez-Ensenat A. Rash as a side-effect of nelfinavir in children. AIDS 2000; 14: 335-6.
8. Rietsema WJ. Fever, erythroderma, abdominal pain and renal failure following initiation of indinavir therapy. Clin Infect Dis 1997; 25: 1268-9.
9. Rijnders B, Kooman J. Severe allergic reaction after repeated exposure to indinavir. Clin Infect Dis 1998: 26: 523-4.
10. Tancrede-Bohin E, Grange F, Bournerias I et al. Hypersensitivity syndrome associated with zalcitabine therapy. Lancet 1996; 347: 971.
11. Saag M, Sonnerborg A, Torres RA et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998; 12: F203-9.
12. Wit F, Wood R, Horban A et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001; 15: 2423-9.
13. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-14.
14. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13: 1419-20
15. Bossi P, Roujeau JC, Bricaire F, Caumes E. Stevens-Johnson syndrome associated with abacavir therapy. Clin Infect Dis 2002; 35: 902.
16. D'Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patient with HIV1 infection. Ann Intern Med 1996; 124: 1019-30.
17. Montaner JSG, Reiss P, Cooper D et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients; the INCAS trial. JAMA 1998; 279: 930-7.
18. Barner A, Myers M. Nevirapine ans rashes. Lancet 1998; 351: 1133.
19. Bonnet F, Lawson-Ayayi P, Thiebaut R et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort 1997-1999. Clin Infect Dis 2002; 35: 1231-7.
20. Havlir D, Cheeseman SH, McLaughlin M et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45.
21. Milpied-Homsi B, Reliquet V, Huart A, Raffi F. Toxicité cutanée de la névirapine utilisée en première intentìon dans le traitement de 100 patients. Ann Dermatol Venereol 1999; 126: 2521.
22. Sissoko D, Ajana F, de la Tribonniere X, Baclet V, Mouton Y. Manifestations cutanées, hépatiques et hématologiques liées à la névirapine: DRESS syndrome? Presse Med 2000; 29: 1041-2.
23. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 1S: 1843-8.
24. Havlir DV, Lange JMA. New antiretrovirals and new combinations. AIDS 1998; 12 (suppl A): S165-74.
25. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-infection in adults. N Engl J Med 1999; 341: 1865-73.
26. Starr SE, Fletcher CV, Spector SA et al. Combination therapy with efavirenz nelfinavir and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999; 341: 1874-81.
27. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000; 30: 227-8.
28. Soriano V, Dona C, Barreiro P, Gonzalez-Lahoz J. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? AIDS 2000; 14: 1672-3.
29. Patel SS, Benfield P. Nevirapine. Clin Immunother 1996; 6: 307-17.
30. Derisi M, Ballard C, Abulhosn K, Colwell B, Barber E, Mathews WC. Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash in program and abstract of the 7th conference on retroviruses and opportunistic infections; San Francisco, january 30-February 2, 2000 (abstract 61).
31. Ho ITY, Wong KH, Chan KCW, Lee SS. High incidence of nevirapine associated rash in HIV-infected chinese. AIDS 1998; 12: 2082-3.
32. Bersoff-Matcha S, Miller W, Aberg J et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 33: 2096-8.
33. Antinoń A, Baldini F, Girardi E et al. Female sex and the use of anti allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15: 1579-81.
34. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non nucleoside reverse transcriptase inhibitor induced rash. AIDS 2002; 16: 1566-8.
35. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002; 34: 1137-42.
36. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
37. Hetherington S, Hughes A, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2.
38. Telenti A, Aubert V, Spertini F. Individualising HIV treatment pharmacogenetics and immunogenetics. Lancet 2002; 359: 722-3.
39. Symonds W, Cutrell A, Edwards M, Steel H, Spreen B, Powell G, McGuirk S, Hetherington S. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24: 565-73.
40. Putterman C, Rahav G, Shalit M, Rubinow A. « Treating through » hypersensitivity to co-trimoxazole in AIDS patients. Lancet 1990; 336: 52.
41. Clay P, Rathbun RC, Siater LN. Managment protocol for abacavir related. Hypersensitivity reaction. Ann Pharmacother 2000; 34: 247-9.
42. Roudier C, Caumes E, Rogeaux O, Bricaire F, Gentilini M. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in the patients with the Acquired Immunodeficiency Syndrome and Pneumocystis carinii pneumonia. Arch Dermatol 1994; 130: 1383-6.
43. Caumes E, Bocquet H, Guermonprez G et al. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin Infect Dis 1995; 21: 656-8.
44. Bocquet H, Bagot M, Roujeau JC. Drug induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia ans systemic symptoms DRESS). Semin Cutan Med Surg 1996; 15: 250-7.
45. Caumes E. Intérêt de La désensibilisation pour réintroduire le triméthoprime-sulfaméthoxazole chez les patients intolérants et infectés par le VIH. Ann Med Interne 1997; 148: 172-6.
46. Demoly P, Messaad D, Fabre J, Reynes J, Bousquet J. Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction. J Allergy Clin Immunol 1999; 104: 504-5.
47. Podzamzer D, Consiglio E, Ferrer E, Gudiol F. Efavirenz associated with corticostéroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS 2000, 14: 331-2.
48. Barreiro P, Soriano V, Casas E et al. Prevention of nevirapine associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-7.
49. Ortega G, Valencia ME, Moreno V, Laguna F, Polo R, Gonzales Lahoz J. Corticosteroids and nevirapine induced toxicity. In Program and Abstracts of the 7th European Conference on clinical aspect and treatment of HIV infection, October 29-27 1999, Lisbon, Portugal (Abstract 1126).
50. Rey D, Partisani M, Krantz V et al. Prednisolone does not prevent the occurrence of nevirapine-induced rashes. AIDS 1999; 13: 2307.
51. Knobel H, Miro JM, Domingo P et al. Failure of a short-term prednisone regimen nevirapine associated rash: a double blind placebo controlled trial. The GESIDA 09/99 Study. J Acquir Immune Defic Syndr 2001; 28: 14-8.
52. Launay O, Roudière L, Boukli N et al. A randomized, double blind, placebo - controlled study on the effect of cetirizine for prevention of nevirapine - associated rash; the vizyr trial. In: Program and abstracts of the 2nd International Aids Society Conference on HIV pathogenesis and treatment, July 13-16, 2003, Paris, France (Abstract 550).
53. Anton P, Soriano V, Jimenez-Nacher I et al. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS 1999; 13: 524-5.